CAR T cell Therapy Market

Global CAR T cell Therapy Market Size

The size of the global CAR T cell therapy market was worth USD 2.62 billion in 2024. The global market is anticipated to grow at a CAGR of 13.5% from 2025 to 2033 and be worth USD 8.18 billion by 2033 from USD 2.97 billion in 2025.

CAR T cell therapy is one of the effective treatment options for cancer. CAR T cell therapy is an immunotherapy in which a patient’s T cells are collected and genetically modified to make them capable of attacking and killing cancer cells. The genetically engineered T cells would be infused into the patient’s body to fight the cancer cells. The demand for these therapies is growing significantly due to the benefits of CAR T cell therapies among healthcare providers and patients. On the other side, the adoption and access to CAR T cell therapies are limited due to the high costs associated and unavailability.

MARKET DRIVERS

The growing cancer patient population is one of the major factors propelling the CAR T cell therapy market growth.

The number of people who have cancer is growing significantly worldwide with each year passing. Cancer caused one in every six deaths in 2020, said WHO. As per the data published by the Centers for Disease Prevention and Control (CDC), an estimated 1,752,735 new cancer cases and 599,589 cancer deaths were recorded in 2019. CAR T cell therapy has gained popularity as one of the effective treatment options to fight against cancer. It has a history of promising results in treating leukemia and lymphoma cancers. Due to this, the adoption of CAR T cell therapies is growing and driving the market growth. To date, the USFDA approved six CAR T cell therapies.

The growing number of initiatives and funding from various governments in favor of CAR T cell therapies is further anticipated to boost the market’s growth rate.

The governments of several countries have taken numerous initiatives to promote awareness regarding CAR T cell therapies among people and funded to conduct of R&D around CAR T cell therapies. For instance, the National Cancer Institute (NCI) invested hefty amounts in the research and development of CAR T cell therapies and established several research centers. In addition, the governments of some countries have extended their support for CAR T cell therapies by providing regulatory support, favorable reimbursement policies, partnering with private companies, and conducting clinical trials. Such initiatives and investments from the governments are anticipated to boost the growth of the CAR T cell therapy market.

The rising investments by the major market participants are estimated to fuel the growth rate of the CAR T cell therapy market.

The key market players such as Novartis and Kite Pharma, have announced that they spend huge amounts on the R&D of CAR T cell therapies to develop new therapies and improve their effectiveness. In addition, the rising number of advancements in the biotechnology industry and growing awareness among healthcare providers and patients regarding the benefits of CAR T cell therapy are boosting the market’s growth rate. Furthermore, implementing advanced technologies and innovative treatment procedures with fewer side effects is expected to surge the market's growth rate. Furthermore, the growing investments in research institutes related to cell therapy are another considerable factor supporting CAR T cell cancer therapy market growth.

MARKET RESTRAINTS

High costs associated with CAR T cell therapies are one of the major factors hampering the market growth.

CAR T cell therapy costs a bit expensive, which cannot be affordable by ordinary people. In addition, the lack of awareness in rural areas regarding the therapeutic process for cancer disease slightly restrains the CAR T cell therapy market's growth rate. Furthermore, an increasing adverse drug reaction concern with cell therapy in Cytokine syndrome problems and neurological problems is expected to hamper the CAR T cell therapy market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Target Antigen Insights

Segments such as CD19 and CD22 accounted for the largest share of the global CAR T cell therapy market in 2024 and are expected to continue their dominance throughout the forecast period. Recently, several companies got their antigens approved. As a result, it also increases the CAR T-cell therapy market.

However, B-cell maturation antigens are anticipated to fastest growth due to their distinctive antigens such as MUC16, ROR1, and L1CAM.

By Application Insights

The multiple myeloma segment captured the major share of the global CAR T cell therapy market in 2024 and is anticipated to continue its domination throughout the forecast period.

The chronic lymphocytic leukemia segment is expected to grow at a notable CAGR during the forecast period.

The Diffuse large B-cell lymphoma (DLBCL) segment is another lucrative segment and is forecasted to hold a considerable share of the worldwide market during the forecast period.

By Product Insights

The autologous segment is anticipated to lead the CAR T Cell therapy market during the forecast period owing to the several potential competitors.

By Therapies Insights

The axicabtagene ciloleucel (Yescarta) segment is expected to have a notable share of the global CAR T cell therapy market during the forecast period owing to the developing healthcare infrastructure and growing discretionary expenses.

By End User Insights

The biotechnology and pharmaceutical companies segment had a major share of the CAR T cell therapy market worldwide in 2024. The segment’s domination is expected to continue during the forecast period owing to the advanced research being carried out at the companies.

REGIONAL ANALYSIS

The North American region occupied the most significant share of the global market in 2024, and the region’s domination is expected to continue throughout the forecast period. The region's growth is primarily attributed to factors such as rapid adoption of technological developments, increasing cancer patient population, and growing demand for CAR T cell therapies. In addition, the North American market is estimated to experience significant growth during the forecast period due to academic institutions, government authorities, and several manufacturing industries. The U.S. occupied the major North American market, followed by Canada in 2021. The U.S. market growth is primarily driven by the rapid development and launch of innovative therapies by major market participants to treat Cancer and the large patient pool suffering from cancer.

The European market is another promising regional market for CAR T cell therapies worldwide. It is expected to hold a substantial global market share during the forecast period. The growth of the European region is anticipated to be boosted by the growing number of approvals for CAR T cell therapies. For instance, the European Medicine Agency recently approved two CAR T cell therapies, Kymriah and Yescarta. Factors such as growing R&D activities, increasing regulatory approvals for new CAR T cell therapies, and the increasing number of cancer awareness programs across the European region are further anticipated to fuel the growth rate of the European market. Swedish Cancer Institute is pleased to give qualifying patients Chimeric Antigen Receptor (CAR)-T cell therapy, one of the most recent immunotherapy types that has resulted in widespread patient remission since its approval in 2017. However, since CAR-T cell therapy was only recently approved in April 2017, insurance companies still plan policies for FDA-approved therapies, including CAR-T cell therapy.

During the forecast period, Asia-Pacific is estimated to grow rapidly and showcase the fastest CAGR among all the regions worldwide. The growing research and developmental activities and the presence of emerging economies majorly drive the growth of the APAC market. As a result, India, Japan, and China are anticipated to hold a major share of the APAC market in the coming years.

During the forecast period, the Latin American market is predicted to hold a considerable share of the worldwide market. The MEA market is expected to grow at a moderate CAGR in the coming years.

KEY MARKET PLAYERS

Companies playing a leading role in the global CAR T cell therapy market profiled in this report are Mustang Bio, Inc., Celgene Corporation, Bluebird Bio, Inc., CARsgen Therapeutics, Ltd., Novartis International AG, Legend Biotech, Sorrento Therapeutics Inc., Kite Pharma, Inc., Immune Therapeutics, Bellicum Pharmaceuticals, Inc. and Pfizer, Inc.

RECENT HAPPENINGS IN THE MARKET

• In Dec 2019, the Swiss government approved the insurance coverage for CAR T cell therapies from Gilead Sciences' Yescarta and Novartis's Kymriah. This initiative from the Swiss Government significantly reduces the financial burden on cancer patients seeking CAR T cell therapies. In addition, it provides access to CAR T cell therapies to blood cancer patients in need.
• In April 2018, Pfizer partnered with Allogene to enhance growth and business in allogeneic CAR T cell therapies.
• In 2018, the Ziopharm Company partnered with Intrexon to advance and develop CAR T cell cancer therapy treatment for substantial tumor disease.

MARKET SEGMENTATION

This research report on the global CAR T Cell therapy market is segmented and sub-segmented based on target antigen, application, product, therapies, and region.

By Target Antigen

• CD20
• EGFRV III
• CD19
• HER2
• MESO
• CD22
• BCMA
• GD2
• CD30
• HER1
• CD33

By Application

• Multiple Myeloma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Follicular Lymphoma
• Diffuse large B-cell lymphoma
• Acute Lymphoblastic Leukemia

By Product

• Allogeneic
• Autologous

By Therapies

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)

By End User

• Cancer Research Centers
• Hospitals
• Academic and Research Institutes
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa